Kovitz Investment Group Partners LLC cut its holdings in shares of Pfizer Inc. (NYSE:PFE) by 2.3% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 120,045 shares of the biopharmaceutical company’s stock after selling 2,801 shares during the quarter. Kovitz Investment Group Partners LLC’s holdings in Pfizer were worth $5,201,000 as of its most recent SEC filing.
Other hedge funds have also modified their holdings of the company. Bailard Inc. lifted its position in Pfizer by 20.2% during the fourth quarter. Bailard Inc. now owns 31,898 shares of the biopharmaceutical company’s stock valued at $1,392,000 after acquiring an additional 5,352 shares during the last quarter. ClariVest Asset Management LLC lifted its position in Pfizer by 929.5% during the fourth quarter. ClariVest Asset Management LLC now owns 2,615 shares of the biopharmaceutical company’s stock valued at $115,000 after acquiring an additional 2,361 shares during the last quarter. Redpoint Investment Management Pty Ltd lifted its position in Pfizer by 0.7% during the fourth quarter. Redpoint Investment Management Pty Ltd now owns 425,736 shares of the biopharmaceutical company’s stock valued at $18,583,000 after acquiring an additional 3,036 shares during the last quarter. Winch Advisory Services LLC lifted its position in Pfizer by 69.6% during the fourth quarter. Winch Advisory Services LLC now owns 819 shares of the biopharmaceutical company’s stock valued at $36,000 after acquiring an additional 336 shares during the last quarter. Finally, Bollard Group LLC lifted its position in Pfizer by 1.6% during the fourth quarter. Bollard Group LLC now owns 82,192 shares of the biopharmaceutical company’s stock valued at $3,588,000 after acquiring an additional 1,256 shares during the last quarter. Institutional investors own 71.68% of the company’s stock.
Shares of NYSE PFE traded down $0.03 during midday trading on Monday, reaching $36.19. The company had a trading volume of 474,378 shares, compared to its average volume of 20,343,916. The business’s 50-day simple moving average is $35.82 and its 200 day simple moving average is $40.36. The stock has a market cap of $197.90 billion, a P/E ratio of 12.06, a P/E/G ratio of 2.84 and a beta of 0.65. Pfizer Inc. has a 1 year low of $33.97 and a 1 year high of $46.47. The company has a current ratio of 1.47, a quick ratio of 1.21 and a debt-to-equity ratio of 0.60.
Pfizer (NYSE:PFE) last issued its earnings results on Monday, July 29th. The biopharmaceutical company reported $0.80 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.75 by $0.05. Pfizer had a net margin of 23.58% and a return on equity of 28.10%. The firm had revenue of $13.26 billion during the quarter, compared to analysts’ expectations of $13.43 billion. During the same quarter last year, the company posted $0.77 earnings per share. The firm’s revenue was down 1.5% compared to the same quarter last year. Analysts predict that Pfizer Inc. will post 2.81 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be issued a dividend of $0.36 per share. The ex-dividend date is Thursday, November 7th. This represents a $1.44 annualized dividend and a dividend yield of 3.98%. Pfizer’s dividend payout ratio (DPR) is presently 48.00%.
In other Pfizer news, major shareholder Pfizer Inc bought 50,000 shares of Pfizer stock in a transaction that occurred on Tuesday, September 17th. The stock was purchased at an average price of $18.00 per share, with a total value of $900,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Frank A. Damelio sold 153,184 shares of the firm’s stock in a transaction on Tuesday, July 2nd. The stock was sold at an average price of $44.09, for a total transaction of $6,753,882.56. Following the transaction, the executive vice president now directly owns 489,647 shares of the company’s stock, valued at approximately $21,588,536.23. The disclosure for this sale can be found here. Company insiders own 0.09% of the company’s stock.
A number of equities research analysts recently commented on the stock. DZ Bank raised shares of Pfizer from a “sell” rating to a “hold” rating and set a $36.00 target price for the company in a research report on Wednesday, August 28th. UBS Group reaffirmed a “neutral” rating and issued a $43.00 price target on shares of Pfizer in a report on Monday, August 5th. Credit Suisse Group reaffirmed a “neutral” rating on shares of Pfizer in a report on Monday, August 12th. ValuEngine cut shares of Pfizer from a “hold” rating to a “sell” rating in a report on Saturday, September 14th. Finally, Morgan Stanley decreased their price target on shares of Pfizer from $40.00 to $38.00 and set an “equal weight” rating for the company in a report on Tuesday, August 27th. One investment analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and four have issued a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $45.88.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Further Reading: Trading based on a resistance level
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.